Anti CD47 Drugs Market Size
Market Size in USD Bn
CAGR43.1%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 43.1% |
| Market Concentration | High |
| Major Players | Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven and Among Others |
please let us know !
Anti CD47 Drugs Market Analysis
The anti CD47 drugs market is estimated to be valued at USD 0.20 Bn in 2025 and is expected to reach USD 2.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 43.1% from 2025 to 2032. Several major pharmaceutical companies are actively conducting clinical trials for anti-CD47 drugs to treat cancer indicating significant efforts to develop innovative treatment options in oncology.
The anti-CD47 drugs market is expected to witness high growth over the forecast period due to rising cancer incidence globally and increasing R&D investments by companies in developing novel cancer immunotherapies. The market is also driven by the promising clinical trial results of anti-CD47 antibodies that show effectiveness in improving survival rates of cancer patients. If approved, these drugs will have high commercial potential and create new opportunities in the oncology segment.